Last reviewed · How we verify
Vaccine Candidate #4
Vaccine Candidate #4 is a Biologic drug developed by Pfizer. It is currently in Phase 2 development.
Vaccine Candidate #4, also known as V920 Vaccine, is being studied for its safety and immunogenicity in various conditions, including Ebola Virus, Malaria, and Pneumococcal Vaccine, among others. The study, NCT02314923, is a placebo-controlled, dose-response study conducted by Merck Sharp & Dohme LLC.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Pfizer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vaccine Candidate #4 |
|---|---|
| Sponsor | Pfizer |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
- Injection site pain
- Fatigue
- Myalgia
- Pain
- Headache
- Pyrexia
- Erythema
- Injection site swelling
- Swelling
- Arthralgia
- Injection site erythema
- Induration
Key clinical trials
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults (PHASE1, PHASE2)
- First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
- Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age (PHASE1, PHASE2)
- A Study to Learn About mRNA Vaccines Against Influenza in Adults (PHASE2)
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21 (PHASE1)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine) (PHASE1)
- A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaccine Candidate #4 CI brief — competitive landscape report
- Vaccine Candidate #4 updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Vaccine Candidate #4
What is Vaccine Candidate #4?
Who makes Vaccine Candidate #4?
What development phase is Vaccine Candidate #4 in?
What are the side effects of Vaccine Candidate #4?
Related
- Manufacturer: Pfizer — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing